HomeTacrolimus Extended Release CapsulesTacrolimus Extended Release Capsules + Mycophenilic Acid

Does Tacrolimus Extended Release Capsules Interact with Mycophenilic Acid?

Tacrolimus Extended Release Capsules and Mycophenilic Acid have a moderate drug interaction according to U.S. FDA drug labeling data. MPA exposure is higher with tacrolimus extended-release capsules than with cyclosporine. Monitor for MPA-associated adverse reactions and reduce MPA dose as needed. The mechanism involves tacrolimus does not interrupt enterohepatic recirculation of mpa, unlike cyclosporine. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Moderate
Mycophenilic Acid Class
Antimetabolite Immunosuppressant
Management
Monitor for effects
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Tacrolimus Extended Release Capsules and Mycophenilic Acid occurs because tacrolimus does not interrupt enterohepatic recirculation of mpa, unlike cyclosporine. Clinically, this means mpa exposure is higher with tacrolimus extended-release capsules than with cyclosporine. monitor for mpa-associated adverse reactions and reduce mpa dose as needed. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.

What To Tell Your Doctor or Pharmacist

If you are taking Tacrolimus Extended Release Capsules and your doctor is considering prescribing Mycophenilic Acid (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Tacrolimus Extended Release Capsules(Astagraf Xl)+💊 Mycophenilic Acid(Mycophenolic Acid)

Severity & Interaction Details

🟡
moderate
Be aware — moderate interaction
Documented interaction with manageable risk. May require dose adjustment or monitoring.
Severity scale
MinorContra
On record
Yes
Drug A class
Drug B class
Antimetabolite Immunosuppressant
Source
NLP:tacrolimus extended-release capsules

What this means in plain English

MPA exposure is higher with tacrolimus extended-release capsules than with cyclosporine. Monitor for MPA-associated adverse reactions and reduce MPA dose as needed.

What the FDA label says

"Tacrolimus does not interrupt enterohepatic recirculation of MPA, unlike cyclosporine"

📖 Source: NLP:tacrolimus extended-release capsules

Share this result:XFacebookWhatsAppReddit
Add more drugs
Check Tacrolimus Extended Release Capsules and Mycophenilic Acid against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.